Male pattern baldness, or androgenic alopecia, is the most common type of hair loss among men. It usually begins with thinning around the temples and crown, gradually progressing to a receding hairline or a bald spot on top of the head. Genetics and hormones are the primary drivers, but lifestyle and age can also influence its onset.
For many men, hair loss can significantly impact self-confidence, sparking a search for effective treatments.Now, a major breakthrough may be on the horizon. Clascoterone, a drug initially approved for acne treatment, has demonstrated remarkable results in restoring hair growth.
On Wednesday, November 31, 2025, Ireland-based Cosmo Pharmaceuticals released findings from two Phase III clinical trials involving 1,500 men. Participants using the 5% clascoterone topical solution experienced hair growth improvements ranging from 168% to 539% compared to a placebo group.
“With strong efficacy across the two largest Phase III studies, and a favorable safety profile, clascoterone 5% topical solution opens the door to a fundamentally better treatment paradigm for patients,” said Giovanni Di Napoli, CEO of Cosmo Pharmaceuticals. The company also noted that the drug was generally safe and well-tolerated.
If approved by the FDA, clascoterone would become the first new treatment for male pattern baldness in three decades. Interestingly, the drug was first approved in 2020 for acne treatment under Cassiopea, now a subsidiary of Cosmo Pharmaceuticals.
Understanding Male Pattern Baldness
Hair loss from male pattern baldness typically progresses in stages:
- Stage 1: Minimal or no visible hair loss
- Stage 2: Hair begins to thin
- Stage 3: Hairline recedes at the temples, forming an “M” or “U” shape
- Stage 4: Hair loss appears on the crown
- Stage 5: Receding hairline starts connecting with the crown bald spot
- Stage 6: Hair between the temples and crown is lost
- Stage 7: Most scalp hair is gone, leaving only a thin band around the sides
The success of clascoterone could revolutionize hair restoration, offering a scientifically backed option for millions of men affected by male pattern baldness.
